Filing Analysis
Coherus Oncology, Inc. entered into an 'at-the-market' (ATM) sales agreement with Leerink Partners LLC to sell up to $50.0 million in common stock. The proceeds are intended for general corporate purposes and working capital.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
- The need for working capital/general corporate purposes often suggests a desire to bolster cash runway in a micro-cap/growth-stage company.
📋 Key Facts
- Entered into a sales agreement with Leerink Partners LLC on August 28, 2026.
- Aggregate offering price of up to $50.0 million in common stock.
- The offering is an 'at-the-market' (ATM) offering under Rule 415(a)(4).
- Agent commission is up to 3.0% of gross proceeds.
- Shares will be sold pursuant to a shelf registration statement on Form S-3 (File No. 333-291520) declared effective on December 8, 2025.
- Proceeds are designated for general corporate purposes and working capital.
Coherus Oncology, Inc. has announced the issuance of a special dividend in the form of Contingent Value Rights (CVRs) linked to the potential sale or licensing of its remaining biosimilar assets. This move indicates a strategic pivot or liquidation of core legacy assets to provide value to shareholders.
🚩 Red Flags
- Strategic shift involving the disposal of 'Legacy BioSim Assets' suggests a narrowing of business scope or a wind-down of specific divisions.
- Existence of a Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, L.P. that restricts the company's ability to dispose of assets and make CVR payments.
- The CVRs are non-transferable, non-voting, and do not represent equity, offering limited upside control to shareholders.
📋 Key Facts
- Board declared a special dividend of CVRs to be distributed to stockholders of record as of September 30, 2026.
- One CVR will be issued for each share of Common Stock outstanding on the record date.
- CVRs are linked to net cash proceeds from the sale, licensing, or disposal of 'Legacy BioSim Assets' (patents, IP, royalties, cell lines, etc.).
- The CVR term runs from October 7, 2026, to October 7, 2028.
- The company has engaged an investment bank to assist in the sale process for these assets.
- A Loan and Security Agreement dated August 12, 2026, with Innovatus Life Sciences Lending Fund I, L.P. contains restrictions on asset disposition and CVR payments.
Coherus Oncology, Inc. entered into a $55 million senior secured term loan agreement with Innovatus Life Sciences Lending Fund I, LP to refinance existing debt and provide working capital. The deal extends the company's debt maturity to August 2031 and features a lower interest rate compared to the previous facility.
🚩 Red Flags
- High prepayment penalties (up to 5.00% plus interest) and a significant 10.00% final fee if the company enters insolvency proceedings.
- The loan is secured by a lien on substantially all assets, including intellectual property.
- The interest rate includes a significant floor (6.75% + Prime), which could be high in a low-rate environment.
📋 Key Facts
- Entered into a $55,000,000 senior secured term loan (Tranche A) on August 12, 2026.
- Maturity date is set for August 2031.
- Interest rate is floating: 4.15% plus the greater of the Prime Rate or 6.75%.
- Includes a 36-month interest-only period, which may be extended to 48 months based on revenue and market cap milestones.
- The loan is secured by a lien on substantially all company assets, including intellectual property.
- The company has options to draw additional tranches of $25M and $20M under certain conditions.
- Proceeds were used to repay the prior loan agreement (which had a higher interest rate and earlier maturity in 2029) and for working capital.
Coherus Oncology, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings via press release.
📋 Key Facts
- Report date: August 5, 2026
- Reporting period: Quarter ended June 30, 2026
- The company furnished its financial results through Exhibit 99.1 (Press Release)
- CEO Dennis M. Lanfear signed the report
Coherus Oncology, Inc. dismissed Ernst & Young LLP (EY) as its independent registered public accounting firm and appointed PricewaterhouseCoopers LLP (PwC) effective June 12, 2026.
🚩 Red Flags
- Change of auditor is always a point of scrutiny in micro-cap companies, though the lack of disagreements reduces immediate alarm.
📋 Key Facts
- Dismissal of Ernst & Young LLP (EY) effective June 12, 2026.
- Appointment of PricewaterhouseCoopers LLP (PwC) for the fiscal year ending December 31, 2026.
- Company states there were no 'disagreements' or 'reportable events' with EY during the fiscal years 2024, 2025, or the interim period through June 12, 2026.
- A prior material weakness in internal control over financial reporting regarding inventory account reconciliations (reported in FY2024) was stated as remediated in the FY2025 Annual Report.
Coherus Oncology, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 27, 2026, and a partially adjourned meeting on May 29, 2026. All five proposals, including director elections, auditor ratification, and equity plan increases, were approved.
🚩 Red Flags
- Proposal 4 (reduction of stock option exercise prices) can sometimes be viewed as a red flag regarding previous option pricing or employee retention, though it was approved by shareholders.
📋 Key Facts
- Annual Meeting held May 27, 2026; partially adjourned to May 29, 2026, specifically for Proposal 4.
- Proposal 1: Elected Dennis M. Lanfear and Mats L. Wahlström to the Board until 2029.
- Proposal 2: Ratified Ernst & Young LLP as the independent auditor for fiscal year ending Dec 31, 2026.
- Proposal 3: Approved non-binding 'Say-on-Pay' executive compensation.
- Proposal 4: Approved the reduction in the exercise price of certain outstanding stock options.
- Proposal 5: Approved an increase in common stock reserved for the Amended and Restated 2014 Equity Incentive Award Plan.
Coherus Oncology, Inc. reported its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The report date and the date of the earliest event reported is May 11, 2026.
- The filing covers financial results for the fiscal quarter ended March 31, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the full text of the earnings press release.
Coherus Oncology, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as Exhibit 99.1 to the filing.
📋 Key Facts
- The filing reports financial results for the period ended December 31, 2025.
- The report was filed on March 9, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The report was signed by CEO Dennis M. Lanfear.
Coherus Oncology, Inc. completed a significant public offering of 28.6 million shares of common stock at $1.75 per share. The company raised approximately $47 million in net proceeds to fund operations or other corporate purposes.
🚩 Red Flags
- Significant dilution: Issuance of 28.6 million new shares represents substantial potential dilution to existing shareholders.
- Low share price: The offering price of $1.75 suggests the company is operating in a low-priced/penny stock territory, which often correlates with higher volatility and liquidity risks.
📋 Key Facts
- Completed sale and issuance of 28,600,000 shares of Common Stock on February 17, 2026.
- Public offering price was $1.75 per share; underwriters purchased at $1.645 per share.
- Net proceeds totaled approximately $47 million (before estimated offering expenses).
- Underwriters included TD Securities (USA) LLC, Guggenheim Securities, LLC, and Oppenheimer & Co. Inc.
- Includes an over-allotment option for up to 4,290,000 additional shares.
- Lock-up agreement prevents company directors, officers, and certain stockholders from selling stock for 60 days after February 12, 2026.
Coherus Oncology, Inc. has entered into a clinical supply agreement with Janssen Research & Development, LLC to evaluate the combination of Coherus's CHS-114 and Janssen's pasritamig in a Phase 1b clinical study for metastatic castration-resistant prostate cancer.
📋 Key Facts
- Agreement date: February 4, 2026
- Partner: Janssen Research & Development, LLC
- Study Type: Phase 1b clinical trial
- Indication: Metastatic castration-resistant prostate cancer (mCRPC)
- Compounds involved: tagmokitug (CHS-114) and pasritamig
- Commercial rights: Both companies retain all commercial rights to their respective compounds, including monotherapy or combination treatments.
Coherus Oncology, Inc. has filed a prospectus supplement to its existing Sales Agreement with TD Cowen (formerly Cowen and Company LLC). This allows the company to offer and sell up to $64.88 million in common stock.
🚩 Red Flags
- Potential dilution for existing shareholders due to the issuance of new common stock.
- The use of an 'at-the-market' style sales agreement often indicates a need for immediate liquidity, which can be a sign of cash burn concerns in micro-cap/growth biotech companies.
📋 Key Facts
- The filing relates to an existing Sales Agreement originally dated November 8, 2022.
- The offering involves shares of common stock with a par value of $0.0001 per share.
- The aggregate offering price is up to $64,880,054.
- The sales agent/underwriter is TD Securities (USA) LLC (TD Cowen).
- A legal opinion from Latham & Watkins LLP was filed as Exhibit 5.1.
Coherus Oncology, Inc. announced it will present preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2025, at the upcoming J.P. Morgan Healthcare Conference.
🚩 Red Flags
- Forward-looking statements include risks regarding the company's ability to raise funds on acceptable terms.
- Potential for material variance between preliminary results and final audited figures.
📋 Key Facts
- Company to disclose preliminary net revenues for Q4 and FY 2025 on January 13, 2026.
- Financial results include cash, cash equivalents, and investments as of December 31, 2025.
- Information is being provided via a presentation at the 43rd Annual J.P. Morgan Healthcare Conference (Exhibit 99.1).
- Results are preliminary, unaudited, and subject to change upon completion of financial closing procedures.
The filing appears to be a technical data dump of XBRL taxonomy elements and metadata rather than a narrative 8-K report. It contains extensive financial tagging for Coherus Oncology, Inc. covering various fiscal years (2022–2024) and complex accounting structures.
🚩 Red Flags
- Presence of significant 'Discontinued Operations' (Udenyca, Yusimry) suggests restructuring or divestiture activity.
- Extensive use of Level 3 Fair Value measurements for contingent consideration and derivative financial instruments, indicating high valuation uncertainty.
- High complexity in debt structure involving convertible notes and multiple term loans.
📋 Key Facts
- The filing includes data related to 'Convertible Senior Subordinated Notes Due 2026' with a 1.5% rate.
- Contains extensive tagging for various product franchises including Toripalimab, Udenyca, Yusimry, and Cimerli.
- Includes significant detail on 'Discontinued Operations' related to the Udenyca business and Yusimry Immunology franchise.
- Lists multiple debt instruments including Term Loans from Biopharma Credit Investments VGp Llc and Ankura Trust Company Llc.
Coherus Oncology, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2025. The filing serves as a formal announcement of the earnings release issued on November 6, 2025.
📋 Key Facts
- The company reported financial results for the fiscal quarter ended September 30, 2025.
- The press release containing the detailed results is attached as Exhibit 99.1.
- Filing date: November 6, 2025.
Coherus Oncology, Inc. has regained compliance with Nasdaq's minimum bid price requirement after meeting the necessary closing price criteria. The company is now in full compliance with all continued listing standards of the Nasdaq Global Market.
🚩 Red Flags
- Historical delisting risk (though resolved in this filing)
📋 Key Facts
- Received a deficiency notice on June 30, 2025, due to the stock trading below $1.00 for 30 consecutive business days.
- The company had until December 29, 2025, to regain compliance via the 180-day grace period.
- Nasdaq confirmed on September 5, 2025, that the stock met the $1.00 minimum bid price requirement for the requisite period.
- The matter regarding Listing Rule 5550(a)(2) is now officially closed.
Coherus Oncology, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings release issued on August 7, 2025.
📋 Key Facts
- Company announced fiscal quarter results for the period ending June 30, 2025.
- The press release containing the financial results is attached as Exhibit 99.1.
- Filing date: August 7, 2025.
Coherus Oncology, Inc. received a deficiency notice from Nasdaq because its common stock bid price has closed below $1.00 for 30 consecutive business days. The company has until December 29, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice regarding minimum bid price requirement.
- Potential for a mandatory reverse stock split to regain compliance if the share price does not recover naturally.
- Risk of delisting from Nasdaq Global Market if compliance is not achieved by December 29, 2025.
📋 Key Facts
- Received deficiency notice on June 30, 2025, from Nasdaq Listing Qualifications Department.
- Violation of Nasdaq Listing Rule 5450(a)(1) regarding minimum bid price ($1.00).
- Compliance deadline (Compliance Date) is December 29, 2025.
- To regain compliance, the stock must maintain a minimum closing bid price of $1.00 for at least 10 consecutive business days before the Compliance Date.
- Failure to comply by the first deadline may require a transfer to Nasdaq Capital Market and potentially a reverse stock split to qualify for a second 180-day compliance period.
Coherus Oncology, Inc. held its 2025 Annual Meeting of Stockholders on June 11, 2025. The meeting resulted in the election of three Class II directors and the ratification of Ernst & Young LLP as independent auditors.
📋 Key Facts
- Annual Meeting held virtually on June 11, 2025.
- Total shares outstanding at record date (April 24, 2025): 115,922,573.
- Shares voted in person or by proxy: 75,584,254.
- Elected Jill O’Donnell-Tormey, Ph.D., Michael Ryan, and Ali J. Satvat to the Board of Directors.
- Ratified Ernst & Young LLP as independent auditors for fiscal year ending Dec 31, 2025 (74,500,950 votes in favor).
- Approved non-binding 'Say-on-Pay' advisory resolution regarding executive compensation.
- Approved amendment to the 2014 Employee Stock Purchase Plan (ESPP).
Coherus Oncology, Inc. (formerly Coherus BioSciences, Inc.) has officially changed its corporate name via a Certificate of Amendment to its Certificate of Incorporation and an amendment to its Bylaws, effective May 29, 2025.
📋 Key Facts
- Corporate name changed from Coherus BioSciences, Inc. to Coherus Oncology, Inc.
- The change was implemented by filing a Certificate of Amendment with the Secretary of State of Delaware on May 29, 2025.
- The Name Change did not require stockholder approval and does not affect shareholder rights.
- Stock symbol 'CHRS' on Nasdaq Global Market remains unchanged.
- CUSIP number for common stock remains unchanged.
Coherus BioSciences, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025. The filing serves as a formal notification that a press release containing these results was issued on May 12, 2025.
📋 Key Facts
- The company reported financial results for the fiscal quarter ending March 31, 2025.
- Results were released via press release (Exhibit 99.1) on May 12, 2025.
- CEO Dennis M. Lanfear signed the report.
Coherus BioSciences announced that Board member Mark D. Stolper will not stand for re-election at the 2025 Annual Meeting, though he will remain as a consultant through late 2026. The filing also details administrative board reclassifications to ensure class balance per the company's Certificate of Incorporation.
🚩 Red Flags
- Reduction in the total number of authorized directors from ten to nine.
📋 Key Facts
- Mark D. Stolper notified the Board of his intention not to stand for re-election at the 2025 Annual Meeting of Stockholders.
- Mr. Stolper will continue to serve on the Board until immediately prior to the 2025 Annual Meeting election.
- Mr. Stolper is expected to provide consulting services through December 31, 2026.
- The Board has reduced its authorized size to nine directors effective upon Mr. Stolper's departure.
- Rita A. Karachun and Michael Ryan underwent immediate resignation/reappointment cycles to rebalance Board classes (Class II to Class I and Class III to Class II, respectively).
Coherus BioSciences announced the resignation of Chief Commercial Officer Paul Reider, effective April 30, 2025. The departure follows the company's divestiture of its UDENYCA franchise, which was its final biosimilar product.
🚩 Red Flags
- Loss of key commercial leadership following the divestiture of the company's last biosimilar product, signaling a major shift in business model or pipeline.
- Significant severance/retention costs including extended salary and equity vesting through 2026.
📋 Key Facts
- Paul Reider resigned as Chief Commercial Officer effective April 30, 2025.
- The resignation is triggered by the completion of the Company’s divestiture of its UDENYCA franchise.
- Reider will provide part-time advisory services to the executive leadership team until April 30, 2026.
- Severance package includes 12 months of base salary and COBRA reimbursement through Dec 31, 2026.
- Unvested equity (options/RSUs) will have its vesting period extended to December 31, 2026.
Coherus BioSciences has completed the divestiture of its UDENYCA® franchise to Intas Pharmaceuticals for $483.4 million in upfront cash. This transaction, alongside previous sales of YUSIMRY and CIMERLI franchises, marks a complete strategic shift as the company's entire biosimilar business will now be presented as discontinued operations.
🚩 Red Flags
- Complete exit from the biosimilar business model (strategic pivot/discontinued operations).
- Significant restructuring of financial statements as all previous core franchises are now 'discontinued operations'.
- Heavy reliance on milestone payments and cash proceeds to fund debt repayment/operations.
📋 Key Facts
- Completed UDENYCA® divestiture to Intas Pharmaceuticals for $483.4 million upfront cash (includes $118.4 million for product inventory).
- Eligible for two milestone payments of $37.5 million each based on Net Sales targets ($300M and $350M thresholds).
- Approximately 40 full-time employees transferred to Intas's U.S. subsidiary effective April 14, 2025.
- Company expects to repurchase its 1.500% Convertible Senior Subordinated Notes on April 15, 2025.
- The company is restructuring; all biosimilar franchises (CIMERLI, YUSIMRY, and UDENYCA) are being moved to discontinued operations.
Coherus BioSciences is divesting its UDENYCA® franchise to Intas Pharmaceuticals and simultaneously executing a massive $170 million repurchase of its 1.5% Convertible Senior Subordinated Notes due 2026. This restructuring is designed to facilitate the asset sale and significantly reduce the company's debt profile.
🚩 Red Flags
- Significant divestiture of a product franchise (UDENYCA) which may impact long-term revenue streams.
- Large cash outlay ($170M+) for debt repurchase indicates urgent need to clean up the balance sheet or manage convertible dilution.
📋 Key Facts
- Divestiture of UDENYCA® (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals Ltd.
- Repurchase of approximately $170 million aggregate principal amount of 1.5% Convertible Senior Subordinated Notes due 2026 at 100% of principal plus accrued interest.
- Post-repurchase, approximately $60 million in Convertible Notes will remain outstanding.
- The company intends to trigger a 'Fundamental Change Repurchase Right' for the remaining notes following the transaction closing.
- Amendments to the Indenture were approved by a majority of noteholders via supplemental indenture dated March 31, 2025.
Coherus BioSciences, Inc. announced that stockholders approved the divestiture of its UDENYCA® (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals Ltd. via a special meeting held on March 11, 2025.
🚩 Red Flags
- Asset divestiture can sometimes indicate a need for liquidity or strategic narrowing of focus.
📋 Key Facts
- Stockholders approved the Asset Purchase Agreement entered into on December 2, 2024.
- The transaction involves the divestiture of the UDENYCA® (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals Ltd.
- A total of 72,579,487 shares were voted at the Special Meeting held on March 11, 2025.
- The proposal received significant support with 70,989,067 votes 'FOR' and only 968,989 votes 'AGAINST'.
Coherus BioSciences, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal notice of the press release containing these earnings results.
📋 Key Facts
- Report date: March 10, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The company issued a press release (Exhibit 99.1) regarding financial results.
- The information in Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Coherus BioSciences is providing supplemental disclosures in response to shareholder demand letters and litigation regarding the proposed sale of its UDENYCA franchise to Intas Pharmaceuticals Ltd. The filing includes updated background information on the sales process and expanded financial fairness opinions from J.P. Morgan.
🚩 Red Flags
- Active litigation (four complaints) in New York Supreme Court challenging the adequacy of transaction disclosures.
- Shareholder demand letters alleging incomplete information regarding the asset sale.
📋 Key Facts
- The company is seeking stockholder approval for the sale of the UDENYCA (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals Ltd.
- Four complaints have been filed in the Supreme Court of the State of New York alleging disclosure deficiencies in the Proxy Statement.
- J.P. Morgan's fairness opinion provides an implied consideration range of $205 million to $1,060 million for the UDENYCA business.
- The total implied consideration is approximately $530 million, consisting of ~$483 million upfront and ~$47 million in risk-adjusted earnouts.
- Nine potential counterparties were contacted during the sales process; six executed NDAs with standstill provisions.
Coherus BioSciences announced it will present preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2024, at the J.P. Morgan Healthcare Conference. The company also noted temporary supply allocation for its product UDENYCA due to high demand.
🚩 Red Flags
- Preliminary results are unaudited and subject to significant change as closing procedures are incomplete.
📋 Key Facts
- Preliminary unaudited net revenues for Q4 and FY 2024 to be presented on January 13, 2025.
- Preliminary unaudited cash, cash equivalents, and investments as of December 31, 2024 to be disclosed.
- Company reports strong demand for UDENYCA in Q4 2024 and into Q1 2025.
- UDENYCA presentations are being temporarily allocated due to high demand.
Coherus BioSciences, Inc. announced the resignation of Kimberly J. Tzoumakas from its Board of Directors, effective December 31, 2024. The company stated that her departure is not due to any disagreement regarding operations, policies, or practices.
📋 Key Facts
- Kimberly J. Tzoumakas resigned from the Board of Directors on November 27, 2024.
- The resignation becomes effective on December 31, 2024.
- The company explicitly stated there was no disagreement with the Company regarding operations, policies, or practices.
Coherus BioSciences has entered into a definitive agreement to divest its UDENYCA® franchise to Intas Pharmaceuticals Ltd. for $483.4 million in cash, subject to stockholder approval and regulatory clearances.
🚩 Red Flags
- Significant divestiture of a core product franchise (UDENYCA®) which may impact future revenue streams.
- Transaction is subject to stockholder approval and significant regulatory hurdles (HSR Act, CFIUS).
- Existence of substantial termination fees ($16.8M) indicates high stakes and potential for deal failure.
📋 Key Facts
- Transaction value: $483.4 million in cash (includes $118.4 million of product inventory).
- Buyer: Intas Pharmaceuticals Ltd.
- Asset being sold: UDENYCA® (pegfilgrastim-cbqv) franchise, including the UDENYCA ONBODY™ presentation.
- Earn-out potential: Two additional payments of $37.5 million each based on Net Sales milestones ($300M and $350M thresholds).
- Expected closing: First quarter of 2025.
- Termination fee: $16.8 million payable by Coherus if it enters an alternative acquisition agreement; $1.0 million payable by Coherus in other specified circumstances.
Coherus BioSciences, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2024. The filing serves as a formal notice that a press release containing these results was issued on November 6, 2024.
📋 Key Facts
- The company reported financial results for the fiscal quarter ended September 30, 2024.
- The announcement was made via press release dated November 6, 2024.
- Full details of the results are contained in Exhibit 99.1.
Coherus BioSciences announced a temporary supply interruption for its UDENYCA product line due to capacity constraints at a third-party Contract Manufacturing Organization (CMO) responsible for final packaging. The company expects channel supply to be depleted by mid-October, with manufacturing expected to resume in late October and availability resuming in early November 2024.
🚩 Red Flags
- Temporary revenue impact expected due to product shortage in Q4 2024.
- Reliance on third-party CMOs for critical final packaging/labeling stages.
📋 Key Facts
- Supply interruption is limited to labeling and final packaging; active pharmaceutical ingredient (API) and drug product components remain available.
- Channel supply for UDENYCA is projected to be substantially depleted by mid-October 2024.
- Manufacturing at the current CMO is expected to resume in mid-October, with product availability resuming in early November 2024.
- The company has engaged a second packaging and labeling CMO; commercial supply from this new facility is expected in Q1 2025.
- Strategic investments since 2021 include $30M+ to diversify the supply chain, including $25M for drug substance manufacturing and $6M for drug product fill manufacturing.
- The company expects these supply chain improvements to reduce UDENYCA production costs by approximately one-third.
- Reaffirmed 2024 R&D and SG&A expense guidance of $250 million to $265 million.
Coherus BioSciences announced the appointment of Bryan McMichael as Chief Financial Officer, effective August 1, 2024. Mr. McMichael transitions from his role as Interim CFO to the permanent position.
🚩 Red Flags
- None identified in this specific filing; the transition is from an interim role to a permanent one within the existing leadership structure.
📋 Key Facts
- Bryan McMichael appointed as Chief Financial Officer effective August 1, 2024.
- McMichael will continue serving as Principal Financial Officer and Principal Accounting Officer.
- Compensation includes a base salary increase to $476,157.06 and a target discretionary bonus threshold of 50% of base salary.
- Grant of stock options to purchase 75,000 shares of common stock at the closing price on the date of grant.
- The company also issued a press release regarding financial results for the fiscal quarter ended June 30, 2024.
Coherus BioSciences entered into an exclusive license and distribution agreement with Apotex, Inc. for the commercialization of toripalimab in Canada. The deal includes a $6.25 million upfront payment and potential milestone payments totaling up to CAD 51.5 million.
🚩 Red Flags
- Revenue sharing: Coherus acts as a pass-through for sales revenue to Junshi Biosciences, retaining only a 'low double-digit percentage' of net sales.
- Termination clauses: The agreement can be terminated by Apotex for any reason after a specified notice period.
📋 Key Facts
- Entered into an exclusive license and distribution agreement with Apotex, Inc. on June 27, 2024.
- The agreement grants Apotex exclusive rights to commercialize toripalimab in Canada.
- Apotex will pay Coherus a $6.25 million USD upfront payment.
- Milestone payments totaling up to CAD 51.5 million are contingent on regulatory and sales achievements.
- Coherus will receive a low double-digit percentage of future net sales in Canada, which it will then pass to Junshi Biosciences per their existing Collaboration Agreement.
- The agreement term lasts until 10 years after the first commercial sale in Canada, with an option for a 10-year extension.
Coherus BioSciences, Inc. has completed the divestiture of its YUSIMRY (adalimumab-aqvh) franchise to Hong Kong King-Friend Industrial Company Ltd. for $40 million in cash. This sale includes all intellectual property, inventory, and R&D activities related to the product.
🚩 Red Flags
- Divestiture of a core franchise (YUSIMRY) suggests a strategic shift or a need for immediate liquidity/cash infusion.
- The filing notes multiple 'Combined Transactions' including two major divestitures and one acquisition, indicating significant corporate restructuring.
📋 Key Facts
- Divestiture of YUSIMRY (adalimumab-aqvh) franchise completed on June 26, 2024.
- Transaction value: $40.0 million upfront all-cash consideration.
- Buyer: Hong Kong King-Friend Industrial Company Ltd. (parent of Meitheal Pharmaceuticals, Inc.).
- Included assets: Intellectual property, contracts, inventory, and R&D activities related to YUSIMRY.
- Assumed liabilities by buyer include $17.0 million in inventory purchase commitments.
- The filing includes pro forma financial information reflecting this sale alongside the CIMERLI divestiture and the Surface Oncology acquisition.
Coherus BioSciences, Inc. announced the appointment of Rita A. Karachun to its Board of Directors and Audit Committee. The appointment includes an expansion of the authorized number of directors from ten to 11.
📋 Key Facts
- Rita A. Karachun appointed as a Class II director effective May 31, 2024.
- Board size increased from 10 to 11 members.
- Ms. Karachun will serve on the Audit Committee.
- Annual cash retainer of $60,000 for board and audit committee service.
- Grant of 168,000 stock options with a three-year vesting schedule (1/3rd after one year, then monthly).
- Ms. Karachun previously served as SVP and Global Controller at Merck & Co., Inc.
Coherus BioSciences, Inc. held its 2024 Annual Meeting of Stockholders on May 29, 2024. The meeting resulted in the election of three directors and the ratification of Ernst & Young LLP as independent auditors.
🚩 Red Flags
- Relatively low participation rate: Approximately 71% of outstanding shares were voted (80.5M out of 113.5M).
📋 Key Facts
- Annual Meeting held virtually via the Internet on May 29, 2024.
- Total shares outstanding at record date (April 9, 2024): 113,498,415.
- Total votes cast: 80,526,896 shares.
- Elected Lee N. Newcomer, MD, Charles W. Newton, and Kimberly J. Tzoumakas to the Board of Directors.
- Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024 (79,827,737 votes in favor).
- Approved non-binding 'Say-on-Pay' advisory resolution regarding executive compensation.
- Approved amendment and restatement of the 2014 Equity Incentive Award Plan.
This 8-K/A filing amends a previous report to include the full Loan Agreement and a Revenue Participation Right Purchase and Sale Agreement dated May 8, 2024. The company has entered into a senior secured term loan facility and a revenue participation agreement with Coduet Royalty Holdings, LLC.
🚩 Red Flags
- Use of revenue participation rights suggests a need for immediate liquidity or non-traditional financing.
- Senior secured term loan indicates potential increase in debt burden and collateralization of assets.
📋 Key Facts
- Entered into a Senior Secured Term Loan Facility on May 8, 2024.
- Entered into a Revenue Participation Right Purchase and Sale Agreement with Coduet Royalty Holdings, LLC on May 8, 2024.
- The filing is an amendment (8-K/A) to provide exhibits previously omitted from the original filing.
Coherus BioSciences, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024. The filing serves as a formal notification of the issuance of a press release containing quarterly earnings data.
📋 Key Facts
- Reporting period: Fiscal quarter ended March 31, 2024.
- Filing date: May 9, 2024.
- The filing includes Exhibit 99.1, which contains the full text of the earnings press release.
- The information provided under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Coherus BioSciences entered into a $38.7 million senior secured term loan to repay existing debt and signed a $37.5 million revenue participation agreement, effectively trading future sales of UDENYCA and LOQTORZI for immediate liquidity.
🚩 Red Flags
- Heavy reliance on alternative financing: The company is selling a percentage of future revenue (Revenue Participation Right), which can significantly impact future margins and cash flow.
- High cost of capital: The revenue participation agreement has an effective multiple of 2.25x, representing a high implicit cost of funding.
- Asset encumbrance: The term loan is secured by substantially all company assets including IP.
- Debt restructuring/Refinancing: Replacing one debt obligation with another (and adding revenue-based obligations) suggests ongoing liquidity management challenges.
📋 Key Facts
- Entered into a senior secured term loan facility of up to $38.7 million with Ankura Trust Company, LLC as agent.
- Term loan matures on May 8, 2029, with an interest rate of 8.00% per annum plus a three-month SOFR.
- The term loan is secured by a lien on substantially all company assets, including intellectual property.
- Entered into a Revenue Participation Right Purchase and Sale Agreement with Coduet Royalty Holdings, LLC for $37.5 million.
- In exchange for the revenue participation, the Company will pay mid-single digit percentage of U.S. net sales of UDENYCA and LOQTORZI until the purchaser receives 2.25x the purchase price.
- Repaid existing debt to BioPharma Credit, PLC (previously $75 million principal) in full.
Coherus BioSciences, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the company's annual earnings release.
📋 Key Facts
- Report date: March 13, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes an earnings press release as Exhibit 99.1
- The information provided under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Coherus BioSciences completed the divestiture of its CIMERLI ophthalmology franchise to Sandoz Inc. for approximately $187.8 million in cash and inventory. The transaction includes a mandatory partial prepayment of $175 million toward the company's existing loan obligations.
🚩 Red Flags
- Significant reduction in debt principal ($175M of $250M) via asset sale suggests liquidity management rather than pure growth strategy.
- The company is using a major asset divestiture to meet upcoming debt obligations (prepayment due April 1, 2024).
📋 Key Facts
- Completed sale of Coherus Ophthalmology LLC (CIMERLI franchise) to Sandoz Inc. on March 1, 2024.
- Upfront cash consideration: $170.0 million.
- Additional consideration for inventory and prepaid manufacturing assets: $17.8 million.
- Mandatory partial prepayment of $175.0 million toward existing loans due on or before April 1, 2024.
- Includes a $6.8 million prepayment premium/make-whole amount to be paid to lenders.
Coherus BioSciences, Inc. announced the appointment of Georgia Erbez to its Board of Directors and Audit Committee. This move increases the size of the Board from nine to ten directors.
📋 Key Facts
- Appointment date: February 20, 2024.
- Georgia Erbez appointed as a Class III director and member of the audit committee.
- Board size increased from nine to ten directors.
- Ms. Erbez will receive an annual cash retainer of $50,000.
- Ms. Erbez received an option to purchase 54,000 shares of common stock, vesting monthly over three years.
- Ms. Erbez has significant biotech leadership experience, including former COO of Walking Fish Therapeutics and CFO of Harpoon Therapeutics.
Coherus BioSciences entered into a Consent, Partial Release and Third Amendment to its existing loan agreement with Biopharma Credit PLC. The amendment facilitates the sale of assets to Sandoz Inc. and requires a $175 million principal prepayment.
🚩 Red Flags
- Significant cash outflow required: The company must make a $175 million principal prepayment, which may impact liquidity depending on the proceeds from the Sandoz asset sale.
- Covenant adjustment: The modification of 'minimum net sales covenant levels' suggests the company was potentially at risk of breaching existing financial performance requirements.
📋 Key Facts
- Entered into 'Consent and Amendment' on February 5, 2024, with Biopharma Credit PLC (Collateral Agent) and Lenders (BPCR Limited Partnership and Biopharma Credit Investments V (MASTER) LP).
- The amendment provides consent for the consummation of a Purchase Agreement with Sandoz Inc. dated January 19, 2024.
- Requires a partial prepayment of $175,000,000 toward the principal of loans under the Existing Loan Agreement upon completion of the Sandoz transaction.
- The amendment includes an adjustment to the minimum net sales covenant level under the existing loan agreement.
Coherus BioSciences has entered into a definitive agreement to divest its CIMERLI ophthalmology franchise and supporting commercial infrastructure to Sandoz Inc. for $170 million in cash, plus inventory adjustments.
🚩 Red Flags
- Significant divestiture of a product franchise and its entire commercial infrastructure, which may impact future revenue streams.
- Transaction is subject to regulatory (Antitrust) approval, creating execution risk.
📋 Key Facts
- Transaction Date: Agreement entered on January 19, 2024.
- Divestiture Target: CIMERLI (ranibizumab-eqrn) ophthalmology franchise and commercial infrastructure.
- Buyer: Sandoz Inc.
- Consideration: $170,000,000 in cash plus an amount for product inventory subject to adjustments.
- Expected Closing: On or before April 19, 2024 (subject to a possible 30-day extension).
- Conditions: Subject to customary closing conditions including Hart-Scott-Rodino Antitrust Act expiration/termination.
Coherus BioSciences, Inc. announced it will present preliminary unaudited revenue for the fiscal year ended December 31, 2023, at the J.P. Morgan Healthcare Conference on January 10, 2024.
🚩 Red Flags
- Preliminary financial results have not been audited or reviewed by the independent registered public accounting firm.
📋 Key Facts
- Company to present preliminary unaudited revenue for FY2023 at the 42nd Annual J.P. Morgan Healthcare Conference.
- Presentation date: January 10, 2024.
- Financial results are based on currently available information and closing procedures are not complete.
- Final results may vary materially from preliminary unaudited results.
Coherus BioSciences has issued a notice of termination to Shanghai Junshi Biosciences regarding the TIGIT Program (CHS-006) as part of a broader portfolio prioritization strategy. While work on this specific program will wind down, the company will continue supporting current patient studies and maintains its collaboration for LOQTORZI™.
🚩 Red Flags
- Termination of a collaborative R&D program suggests a narrowing focus or potential lack of confidence in the TIGIT candidate's commercial viability compared to other pipeline assets.
📋 Key Facts
- Termination notice delivered to Shanghai Junshi Biosciences regarding the TIGIT Program (CHS-006) on January 10, 2024.
- The termination is part of a portfolio prioritization process following the acquisition of Surface Oncology, Inc. in September 2023.
- Coherus plans to wind down work on the TIGIT Program over the coming months.
- Current clinical studies (NCT05061628 and NCT05757492) will continue to support existing patients.
- The broader Collaboration Agreement remains active for the development of LOQTORZI™ (toripalimab-tpzi).